- Home
- ACAD vs SXI Comparison
ACAD vs SXI Comparison
Compare ACAD & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SXI
- Stock Information
- Founded
- ACAD 1993
- SXI 1955
- Country
- ACAD United States
- SXI United States
- Employees
- ACAD N/A
- SXI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SXI Industrial Machinery/Components
- Sector
- ACAD Health Care
- SXI Industrials
- Exchange
- ACAD Nasdaq
- SXI Nasdaq
- Market Cap
- ACAD 2.5B
- SXI 2.3B
- IPO Year
- ACAD 2004
- SXI N/A
- Fundamental
- Price
- ACAD $21.57
- SXI $151.11
- Analyst Decision
- ACAD Buy
- SXI Strong Buy
- Analyst Count
- ACAD 14
- SXI 3
- Target Price
- ACAD $27.08
- SXI $223.33
- AVG Volume (30 Days)
- ACAD 3.0M
- SXI 81.6K
- Earning Date
- ACAD 05-07-2025
- SXI 05-01-2025
- Dividend Yield
- ACAD N/A
- SXI 0.85%
- EPS Growth
- ACAD N/A
- SXI N/A
- EPS
- ACAD 1.37
- SXI 5.04
- Revenue
- ACAD $996,283,000.00
- SXI $748,252,000.00
- Revenue This Year
- ACAD $13.49
- SXI $9.67
- Revenue Next Year
- ACAD $10.58
- SXI $12.91
- P/E Ratio
- ACAD $15.76
- SXI $29.90
- Revenue Growth
- ACAD 22.42
- SXI 2.67
- 52 Week Low
- ACAD $13.40
- SXI $128.85
- 52 Week High
- ACAD $25.23
- SXI $212.66
- Technical
- Relative Strength Index (RSI)
- ACAD 68.70
- SXI 49.01
- Support Level
- ACAD $21.95
- SXI $144.62
- Resistance Level
- ACAD $22.62
- SXI $154.21
- Average True Range (ATR)
- ACAD 1.21
- SXI 3.36
- MACD
- ACAD 0.23
- SXI -0.19
- Stochastic Oscillator
- ACAD 56.27
- SXI 35.02
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SXI Standex International Corporation
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.